Figure 2From: Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer Association between the 160-gene prognostic signature, clinical and survival information in 301 untreated lung adenocarcinoma patients from Training Series A patients with at least 12 months follow-up). (A) Prognostic indexes range from −2 to +2 and are associated with an increase in DSS events, as indicated with a black line at (B). (C) Median-centered 160-gene expression profile used to compute the prognostic index (red = relative high expression, green = relative low expression). Each gene in the signature was chosen based on its statistically significant association with outcome, independent to age, stage, grade, gender and smoking history.Back to article page